Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Frist Inoculates Drug Makers for Any Vaccine Liability After Industry Won Him Senate & He Himself Said Anthrax Was Problematic
- SANTA MONICA, Calif., Nov. 16 /U.S. Newswire/ -- Senate Majority Leader Bill Frist is seeking a last-minute amendment to an appropriations bill that would remove legal liability from a drug company if the Bush Administration declares its vaccines are needSANTA MONICA, Calif., Nov. 16 /U.S. Newswire/ -- Senate Majority Leader...
- Research articles 2005-11-16
- Pharma Industry Concerned Over Drug Competition Bill.(Brief Article)
- THE PHARMACEUTICAL industry is concerned over a Senate committee's approval of legislation that would require brand-name drug companies to report to federal officials any time they pay a generic manufacturer to delay market introduction of a lower- THE PHARMACEUTICAL industry is concerned over a...
- Research articles 2001-10-29
- Leahy Plans to Seek Compromise For Drug Monopoly Legislation.(Senate Judiciary Committee )(Government Activity)(Brief Article)
- THE INCOMING chairman of the Senate Judiciary Committee intends to pursue legislation to prevent brand-name drug companies from delaying generic competition. But Sen. Patrick Leahy (D-Vt.), in line to replace current chairman Orrin Hatch (R-U THE INCOMING chairman...
- Research articles 2001-06-04
- What else can be done?
- Byline: Daniel Rome Levine A framework for generic biopharmaceutical drugs is not the only area Congress should act on to help protect employers, health insurers and consumers from rising drug costs: Biodefense legislation The Senate is consider Byline: Daniel Rome Levine...
- Research articles 2006-01-02
- GSK and Others See Massachusetts Showdown Over Drug-Marketing Reform
- There are two ideas floating in the world of politics to curb the way drug companies give doctors gifts and often biased information. One of them is a good idea, and one of them is a bad idea. Drug companies -- such as GlaxoSmithKline -- have chosen...
- Blog posts 2008-08-08
Additional Resources
- Up To $16 Million In Drug Company Stock Investments Conflict 42 U.S. Senators Out of Vaccine Vote, Says FTCR
- SANTA MONICA, Calif., Dec. 13 /U.S. Newswire/ -- Forty-two U.S. Senators hold stock in pharmaceutical companies even as they vote on legislation to benefit the drug industry, according to an analysis released today by the nonprofit, nonpartisan Foundation for Taxpayer and Consumer Rights FTCR. The Senate is expected to...
- Research articles 2005-12-13
- Exelon Ditches U.S. Chamber Over Climate Policy, Who Will Leave the "Voice of Business" Next?
- The U.S. Chamber of Commerce's stance on climate-change legislation continues to alienate its member base. This time it's Exelon, the third utility to desert the U.S. Chamber in a week. It's not quite a exodus. But momentum is building against the powerful lobbying group -- described as...
- Blog posts 2009-09-28
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
- Schering-Plough Now in the Feds' Crosshairs
- The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
- Blog posts 2008-05-07
- DotW: Noble Pursuits
- It's Nobel week and the rewards and riches went to experts who've spent their careers ferreting out the secrets of telomeres medicine, ribosomes chemistry, and fiber optics physics. And then there was Barack Obama, who took home the much vaunted--and in this case highly controversial Nobel for Peace. Who needs...
- News items 2009-10-09
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- << Previous
- page 1 of 1
- Next >>
Presented by American Express